Processa PharmaceuticalsPCSA
About: Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Employees: 13
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.09% less ownership
Funds ownership: 1.57% [Q2] → 1.49% (-0.09%) [Q3]
11% less funds holding
Funds holding: 9 [Q2] → 8 (-1) [Q3]
34% less capital invested
Capital invested by funds: $101K [Q2] → $66.5K (-$34.5K) [Q3]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 133 / 308 met price target | 494%upside $6 | Buy Reiterated | 3 Oct 2024 |
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 133 / 308 met price target | 494%upside $6 | Buy Reiterated | 20 Aug 2024 |
HC Wainwright & Co. Raghuram Selvaraju 43% 1-year accuracy 133 / 308 met price target | 494%upside $6 | Buy Maintained | 19 Aug 2024 |
